Program
Iparomlimab/Tuvonralimab
Also written as “QL1706”, “QL1706 injection” and “QL1706, IV infusion”.
Its studies are mostly in Uterine Cervical Neoplasms · Colorectal Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 2214 open or running | phase 3since Jun 28, 2022 | Jun 4, 2019 | Jun 2027phase 2 · NCT07272590 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Jun 4, 2019.
- Aug 1, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05487391 · 632 planned · China
- Sep 20, 2022Phase 2 study in Uterine Cervical NeoplasmsNCT05557565 · 150 enrolled · China
- Sep 30, 2022Phase 3 study in Nasopharyngeal CarcinomaNCT05576272 · 460 enrolled · China
- Oct 21, 2022Phase 2 study in Advanced Liver CancerNCT05603039 · 80 enrolled · China
- Jan 10, 2023Phase 3 study in Lung NeoplasmsNCT05690945 · 606 enrolled · China
- Mar 23, 2023Phase 2 study in Colorectal NeoplasmsNCT05799820 · 60 planned · China
- Jul 28, 2023Phase 3 study in Carcinoma, HepatocellularNCT05976568 · 668 planned · China
- Jun 1, 2024Phase 2 study in Advanced Solid TumorNCT06446388 · 360 planned · China
- Nov 11, 2024Phase 3 study in Colonic NeoplasmsNCT06686576 · 363 planned · China
- Jan 17, 2025Phase 3 study in Small Cell Lung CarcinomaNCT06789796 · 636 planned
- Feb 20, 2025Phase 2 study in Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNCT06852456 · 30 planned
- Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
- Jun 9, 2025Phase 3 study in Colorectal NeoplasmsNCT07025239 · 430 planned
- Nov 26, 2025Phase 2 study in Metastatic Solid TumorsNCT07272590 · 290 planned
Ahead
- Jun 2027Primary completion: phase 2 study in Metastatic Solid TumorsNCT07272590
- Aug 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05487391
- Sep 1, 2027Primary completion: phase 3 study in Carcinoma, HepatocellularNCT05976568
- Mar 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06789796
TargetBeta
“A mixture of the two engineered monoclonal antibodies iparomlimab, which is an immunoglobulin G4 (IgG4) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and tuvonralimab, which is an IgG1 monoclonal anti”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 45 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07272590Metastatic Solid Tumors | 2 | Not yet recruiting | Jun 2027 | 290 |
| NCT07025239Colorectal Neoplasms | 3 | Not yet recruiting | Jul 2028 | 430 |
| NCT06949761Solid Tumor | 2 | Not yet recruiting | Sep 2026 | 240 |
| NCT06852456Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | 2 | Not yet recruiting | Dec 2030 | 30 |
| NCT06789796Small Cell Lung Carcinoma | 3 | Not yet recruiting | Mar 2028 | 636 |
| NCT06686576Colonic Neoplasms · China | 3 | Recruiting | Dec 2030 | 363 |
| NCT06446388Advanced Solid Tumor · China | 2 | Not yet recruiting | Jun 30, 2026 | 360 |
| NCT05976568Carcinoma, Hepatocellular · China | 3 | Not yet recruiting | Sep 1, 2027 | 668 |
| NCT05799820Colorectal Neoplasms · China | 2 | Recruiting | Mar 30, 2024 | 60 |
| NCT05690945Lung Neoplasms · China | 3 | Active, not recruiting | Jun 2029 | 606 |
| NCT05603039Advanced Liver Cancer · China | 2 | UNKNOWN | Dec 30, 2023 | 80 |
| NCT05576272Nasopharyngeal Carcinoma · China | 3 | Active, not recruiting | Dec 30, 2024 | 460 |
| NCT05557565Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Oct 30, 2022 | 150 |
| NCT05487391Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Aug 31, 2027 | 632 |
| NCT05446883Uterine Cervical Neoplasms · China | 3 | Recruiting | Sep 1, 2024 | 498 |
| NCT05329025Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Jan 1, 2024 | 100 |
| NCT05309629Small Cell Lung Carcinoma · China | 2 | Completed | Feb 1, 2023 | 40 |
| NCT05262413Advanced Renal Cell Carcinoma | 2 | UNKNOWN | Jul 30, 2023 | 60 |
| NCT05179317Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Dec 2022 | 60 |
| NCT05171790Advanced Solid Tumors · China | 1 | UNKNOWN | Dec 31, 2021 | 419 |
| NCT04296994Advanced Malignant Tumor · China | 1 | UNKNOWN | Dec 31, 2021 | 99 |
| NCT03986606Neoplasms · United States | 1 | UNKNOWN | Feb 28, 2021 | 64 |
How it is read
Names in the registry
- “QL1706”, 14 entries
- “QL1706 injection”, 2 entries
- “QL1706, IV infusion”, 1 entry
- “QLC1101+QL1706”, 1 entry
- “Iparomlimab and Tuvonralimab (QL1706)Injection”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Small Cell Lung Carcinoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Colonic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.